|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1997-12-17
|
|
pubmed:abstractText |
In two sequential phase II studies, we evaluate the feasibility and efficacy of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of small-cell lung cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3464-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9396399-Aged,
pubmed-meshheading:9396399-Anemia,
pubmed-meshheading:9396399-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9396399-Carboplatin,
pubmed-meshheading:9396399-Carcinoma, Small Cell,
pubmed-meshheading:9396399-Drug Administration Schedule,
pubmed-meshheading:9396399-Etoposide,
pubmed-meshheading:9396399-Female,
pubmed-meshheading:9396399-Humans,
pubmed-meshheading:9396399-Leukopenia,
pubmed-meshheading:9396399-Lung Neoplasms,
pubmed-meshheading:9396399-Male,
pubmed-meshheading:9396399-Middle Aged,
pubmed-meshheading:9396399-Paclitaxel,
pubmed-meshheading:9396399-Survival Analysis,
pubmed-meshheading:9396399-Thrombocytopenia
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
|
|
pubmed:affiliation |
Sarah Cannon Cancer Center and The Minnie Pearl Cancer Research Network, Nashville, TN 37203, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
